Small Cap Network's  Instablog

Small Cap Network
Send Message
Small Stocks. Big Returns. The SmallCap Network is one of the web's leading small cap stock trading communities. While large caps tend to receive the majority of media attention, small and micro cap stocks as well as penny stocks can often offer the most potential for investment gains. The... More
My company:
SmallCap Network
My blog:
SmallCap Network
  • Immunomedics Inc., (IMMU) Soars Past 49 Percent on Mid-stage Study of Lupus Drug  0 comments
    Aug 27, 2009 4:23 PM | about stocks: IMMU

    Immunomedics Inc., (NASDAQ:IMMU) and Belgian firm UCB Pharmaceutical collaborative tests on drug Epratuzumab show strong results in treating immune disease.

    Gaining 49.06% ($2.09) this morning in early trading is Immunomedics Inc., (IMMU) which is currently trading on the Nasdaq in the $6.07 range. IMMU has a new market cap of $454 million. IMMU has a 3-Month average daily trading volume of 832,258 shares and it topped 7,327,098 shares in early trading on news that its drug for treating auto immune disease Lupus had passed mid-stage tests.

    IMMU and Belgian pharmaceutical group UCB (private) said today that their Lupus fighting drug Epratuzumab had achieved the testing goals of a joint study and the drug was more effective than a placebo at treating symptoms of Lupus.

    In collaboration, IMMU and UCB said the study results showed that the drug was 24.9% higher in symptom improvements than a placebo among 227 patients with moderate to severe systematic Lupus. Immunomedics licensed the drug to UCB Pharma of Belgium in 2006. Lupus is a disease that attacks the body's own immune system. IMMU is also testing Epratuzumab as a treatment for lymphoma.

    IMMU is involved in R&D, manufacture and sales monoclonal antibody-based products for the treatment of cancer, autoimmune diseases, and other serious afflictions.

    The IMMU trials pipeline:

    The lead product candidate is Epratuzumab. Veltuzumab, is in Phase I/II clinical study for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia, and for patients with ITP. IMMU-102, a Y-90-labeled Epratuzumab product candidate is in Phase I/II clinical study for the treatment of patients with non-Hodgkin's lymphoma; and IMMU-107 or PAM4 labeled with Y-90, a humanized monoclonal antibody product, is in Phase I/II dose-escalation trials for the treatment of pancreatic cancer. IMMU products also include: Milatuzumab, a Phase I/II multicenter clinical trial product for the treatment of multiple myeloma, non-Hodgkin's lymphoma, and chronic lymphocytic leukemia; and Labetuzumab, a Phase II clinical trail product that targets carcinoembryonic antigen.

    At $6.07, IMMU is above both its 52-week high of $5.39 set on 07-28-09 and its 52-week low of $0.84 set on 03-06-09. At $6.07, IMMU is ahead of both its 50-day and 300-day moving averages. Its shares out versus float ratio is near-parity.

    Sign-up for Free to Receive Future Commentary and Trading Alerts on IMMU

    Stocks: IMMU
Back To Small Cap Network's Instablog HomePage »

Instablogs are blogs which are instantly set up and networked within the Seeking Alpha community. Instablog posts are not selected, edited or screened by Seeking Alpha editors, in contrast to contributors' articles.

Comments (0)
Track new comments
Be the first to comment
Full index of posts »
Latest Followers


More »
Instablogs are Seeking Alpha's free blogging platform customized for finance, with instant set up and exposure to millions of readers interested in the financial markets. Publish your own instablog in minutes.